With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.
Aakash Desai, MBBS, MPH
Advertisement
Articles by Aakash Desai, MBBS, MPH
Advertisement
Latest Updated Articles
- Neulasta Onpro: A Coup de Grâce?
Published: March 13th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
4
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
5
